STOCK TITAN

Kura Oncology Inc - KURA STOCK NEWS

Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.

Overview of Kura Oncology Inc

Kura Oncology Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company driven by the promise of precision medicines for cancer. Operating at the forefront of the genomics revolution, the company targets cancer signaling pathways with innovative small molecule drug candidates, positioning itself at the nexus of targeted therapy and personalized oncology. With a robust focus on precision medicine, Kura Oncology integrates cutting-edge research and a deep understanding of cancer genetics to develop therapies that are safer and more effective for patients with specific genetic profiles.

Core Business and Pipeline

Kura Oncology’s pipeline reflects its commitment to addressing high unmet medical needs in oncology. The company is developing targeted therapies that interfere with key molecular interactions in cancer cells. A central focus is on ziftomenib, a once-daily, oral menin inhibitor designed to disrupt the menin-KMT2A interaction, which plays a pivotal role in the pathogenesis of acute myeloid leukemia (AML) and other hematologic malignancies. The company’s approach leverages detailed insights into cancer genetics to offer precision treatments capable of identifying and targeting patient-specific cancer profiles.

Scientific Innovation and Market Position

The scientific strategy at Kura Oncology is built on a clear understanding that a patient’s genetic makeup drives treatment response. This knowledge has informed the company’s comprehensive development programs, targeting not only hematologic cancers such as various forms of leukemia and lymphoma but also solid tumors including lung, colorectal, thyroid, and pancreatic cancers. By tailoring its therapeutic approaches based on cancer genomics, Kura Oncology aspires to craft treatments that uniquely address the vulnerabilities of cancer cells, thereby offering enhanced efficacy and minimized toxicity compared to traditional therapies.

Collaborations and Clinical Development

In recognition of the complexities of modern drug development, Kura Oncology has engaged in strategic collaborations with global partners to further its goals. These partnerships enhance its capabilities throughout the clinical and regulatory process, ensuring comprehensive development and streamlined commercialization strategies. Kura’s work on ziftomenib, for instance, has already garnered attention in clinical settings and regulatory agencies, reflecting robust safety and efficacy profiles as observed in multiple clinical studies.

Commitment to Precision Medicine

The company’s mission is not only to develop novel treatments but also to fundamentally change the way cancer is treated by integrating precision medicine into clinical practice. This involves sophisticated diagnostics and companion tests that help identify patients who are most likely to benefit from targeted treatments. Such a model is emblematic of Kura Oncology’s forward-thinking approach, wherein advanced molecular insights drive tailored therapeutic strategies that aim to significantly improve patient outcomes.

Industry Terminology and Strategic Insights

Throughout its operations, Kura Oncology employs industry-specific terminology such as "targeted therapy," "desired pharmacological profiles," and "companion diagnostics" to underscore its technical expertise. By focusing on the genetic underpinnings of cancer, the company not only differentiates itself from more conventional treatment modalities but also reinforces its market position as a specialist in precision oncology. Each element of the company’s strategy is supported by a clear scientific rationale, reflecting a mature and methodical approach to drug discovery and development.

Conclusion

Kura Oncology Inc remains dedicated to advancing the boundaries of cancer therapy with a focus on precision medicine. By combining genetic insights, groundbreaking research, and strategic global collaborations, the company delivers a deep reservoir of expertise in the biopharmaceutical arena. Investors and industry analysts recognize Kura’s distinctive model as it continues to evolve through clinical innovation and development, marking its importance in the competitive landscape of modern oncology.

Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) has appointed Teresa Bair as Chief Legal Officer and Corporate Secretary. Bair brings over 25 years of legal experience, recently serving as General Counsel at Athenex, where she assisted in multiple NDA filings and an FDA approval. Kura's President, Troy Wilson, emphasized her expertise in drug development, crucial for advancing their oncology drug pipeline. Kura focuses on precision medicines for cancer, with pipeline candidates like KO-539 and tipifarnib, which has gained Breakthrough Therapy Designation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
management
-
Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) announced that Troy Wilson, Ph.D., J.D., CEO, will participate in two virtual investor conferences. He will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, with an on-demand recording available starting at 7:00 a.m. ET. Additionally, he will engage in a fireside chat at the Cantor Global Healthcare Conference on September 27, 2021, at 3:20 p.m. ET. Audio webcasts of both events will be accessible on Kura's website, with archived replays available after both events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
conferences
-
Rhea-AI Summary

Kura Oncology reported its Q2 2021 results, highlighting key advancements in clinical trials and collaborations. The first patients have been dosed in the Phase 1b cohorts for KO-539, a menin inhibitor targeting relapsed/refractory AML. A collaboration with Novartis aims to assess tipifarnib with alpelisib in HNSCC. Kura has also nominated KO-2806 as its lead candidate in a new farnesyl transferase program. Financially, the company reported a net loss of $33.7 million with $567.5 million in cash reserves expected to sustain operations into 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
Rhea-AI Summary

Kura Oncology, Inc. (Nasdaq: KURA) announced its participation in the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021. CEO Troy Wilson will join a panel discussion titled “Bullseye - Targeted Oncology Part 2” at 10:20 a.m. ET. A live audio webcast will be accessible via the Investors section of Kura's website, with a replay available shortly after the event. Kura focuses on precision medicines for cancer, currently advancing drug candidates like KO-539 and Tipifarnib in clinical trials targeting specific cancer types.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
conferences
-
Rhea-AI Summary

Kura Oncology, a clinical-stage biopharmaceutical company, will announce its second quarter 2021 financial results on August 5, 2021, after market close. A webcast and conference call will follow at 4:30 p.m. ET. The company is focused on precision medicines for cancer treatment, with several drug candidates including KO-539 for acute myeloid leukemia and tipifarnib for HRAS mutant head and neck squamous cell carcinoma. Kura's therapies aim to target specific cancer pathways and improve patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
conferences earnings
-
Rhea-AI Summary

Kura Oncology, Inc. (Nasdaq: KURA) announced the appointment of Dr. Helen Collins to its board of directors. Dr. Collins, a veteran in medical oncology with over 25 years of experience, previously served as Chief Medical Officer at Five Prime Therapeutics. Her expertise will be instrumental as Kura advances its pipeline, including the KO-539 menin inhibitor in acute myeloid leukemia and the tipifarnib program for HRAS mutant head and neck squamous cell carcinoma. This strategic addition aims to enhance Kura's clinical development efforts and fulfill its mission of precision cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
management
Rhea-AI Summary

Kura Oncology, Inc. announced a clinical collaboration with Novartis to study the combination of tipifarnib and alpelisib for treating head and neck squamous cell carcinoma (HNSCC) driven by HRAS or PIK3CA pathways. This follows promising preclinical results indicating enhanced anti-tumor activity when both drugs target co-dependent pathways. The Phase 1/2 KURRENT trial is set to commence in the second half of 2021, aiming to potentially broaden tipifarnib's application among advanced HNSCC patients. Kura retains global rights to tipifarnib.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.49%
Tags
none
-
Rhea-AI Summary

Kura Oncology announced the dosing of the first patient in the Phase 1b expansion of KOMET-001, targeting relapsed/refractory acute myeloid leukemia (AML) with its selective menin inhibitor, KO-539. The trial includes two cohorts: 200 mg and 600 mg doses, each enrolling at least 12 genetically enriched patients. KO-539 showed promising activity and a favorable safety profile in prior phases. The data obtained will aid in determining the recommended Phase 2 dose and potentially contribute to registration efforts. Kura aims to present future data at medical meetings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
-
Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) announced its participation in the JMP Securities Life Sciences Conference, with CEO Troy Wilson scheduled for a virtual presentation on June 17, 2021, at 3:00 p.m. ET. The live audio webcast will be accessible on Kura's website, with a replay available afterward. Kura focuses on precision medicines for cancer treatment, with promising candidates like KO-539 and Tipifarnib in clinical trials targeting specific cancers, including acute myeloid leukemia and HRAS mutant head and neck cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
conferences
Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) announced the appointment of Carol Schafer to its board of directors, effective June 3, 2021. With over 25 years of experience in healthcare investment banking, including her recent role as Vice Chair of Equity Capital Markets at Wells Fargo Securities, Schafer is expected to contribute significantly to Kura’s strategic initiatives. She will succeed Robert Hoffman, who is stepping down from the board on August 3, 2021, after six years of service. Kura's pipeline includes promising cancer treatment candidates like KO-539 and Tipifarnib.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
management

FAQ

What is the current stock price of Kura Oncology (KURA)?

The current stock price of Kura Oncology (KURA) is $5.89 as of April 4, 2025.

What is the market cap of Kura Oncology (KURA)?

The market cap of Kura Oncology (KURA) is approximately 478.9M.

What is Kura Oncology's primary focus?

Kura Oncology is dedicated to advancing precision medicines for cancer by developing targeted small molecule drugs that address specific genetic profiles in tumors.

Which cancers does Kura Oncology target?

The company focuses on cancers with high unmet needs, including acute myeloid leukemia, as well as various solid tumors such as lung, colorectal, thyroid, and pancreatic cancers.

What is the role of ziftomenib in Kura Oncology's pipeline?

Ziftomenib is a selective, oral menin inhibitor developed to disrupt key protein interactions in cancer cells, particularly targeting mutations in acute myeloid leukemia.

How does Kura Oncology utilize precision medicine?

The company leverages advancements in genomics and companion diagnostics to tailor treatments to the unique genetic makeup of each patient’s cancer, optimizing safety and efficacy.

What types of drug candidates does Kura Oncology develop?

Kura Oncology develops small molecule drug candidates that interfere with cancer signaling pathways, aiming to provide transformative treatment options with improved patient outcomes.

How does Kura Oncology maintain its competitive edge?

Through innovative approaches grounded in cutting-edge research, strategic collaborations, and a focus on precision medicine, Kura Oncology distinguishes itself by targeting genetic vulnerabilities in cancer.

What phase are Kura Oncology's clinical trials in?

As a clinical-stage company, Kura Oncology conducts multiple trials evaluating the safety and efficacy of its drug candidates in patient populations with specific cancer types.

Does Kura Oncology collaborate with other organizations?

Yes, the company has strategic partnerships with global pharmaceutical entities to enhance developmental, regulatory, and commercial capabilities for its therapies.
Kura Oncology Inc

Nasdaq:KURA

KURA Rankings

KURA Stock Data

478.88M
77.98M
1.15%
102.19%
11.41%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO